ERBB2 and gastric cancer: Targeted therapies for GC have been reported as follows: trastuzumab for the treatment of human epidermal growth factor (HER2) positive patients, Ramoximab for specific targeted angiogenesis, and anti-PD-L1(programmed cell death-Ligand 1)/PD-1(programmed death-1) inhibitors for patients with advanced GC, including nivolumab or pembrolizumab (5).